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Abstract 
Background: Data on the influence of glycemic status on the progression of coronary calcification, an important 
marker for future adverse cardiovascular events, are limited.
Methods: Data from the Korea Initiatives on Coronary Artery Calcification (KOICA) registry on 12,441 asympto‑
matic Korean adults (52 ± 9 years, 84.2% males) without previous history of coronary artery disease and stroke, who 
underwent serial coronary artery calcification (CAC) screening examinations, were included in this study. The median 
inter‑scan period was 3.0 (2.0–4.8) years. All participants were categorized into three groups based on their glycemic 
status: normal (n = 6578), pre‑diabetes (n = 4146), and diabetes (n = 1717). CAC progression was defined as a differ‑
ence ≥ 2.5 between the square roots (√) of the baseline and follow‑up CAC scores.
Results: The incidence of CAC progression was significantly different between the three groups (normal, 26.3%; 
pre‑diabetes, 30.9%; and diabetes, 46.9%; p < 0.001). In the univariate logistic analysis, the risk of CAC progression was 
higher in the pre‑diabetes (odds ratio [OR] 1.253; 95% confidential interval [CI] 1.150–1.366) and diabetes (OR 2.471; 
95% CI 2.215–2.758) groups than in the normal group (p < 0.001, both). In the multivariate logistic analysis, the risk of 
CAC progression was not significantly different between the normal and pre‑diabetes groups but was significantly 
higher in the diabetes group than in the normal group.
Conclusions: In asymptomatic subjects, diabetes had an incremental impact on CAC progression; however, pre‑
diabetes did not increase the risk of CAC progression after adjusting for confounding factors.
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Background
Diabetes is one of the major causes of cardiovascular 
(CV) morbidity and mortality worldwide. Several meta-
analyses have reported that diabetes increases the risk of 
developing coronary artery disease (CAD) two to three-
fold [1–4]. It is well-known that diabetes is associated 
with an increased risk of CAD after adjusting for other 
traditional CV risk factors. However, uncertainty remains 
as to whether a pre-diabetic condition is independently 
associated with the progression of coronary atherosclero-
sis [5, 6].
Coronary artery calcification (CAC) is associated with 
atherosclerotic burden and adverse CV clinical outcomes 
[7–10]. Furthermore, CAC progression is a powerful pre-
dictor of mortality over the baseline CAC score and tra-
ditional CV risk factors [11]. Therefore, this study aimed 
to explore the association between glycemic status and 
CAC progression in an asymptomatic Korean population 
using serial cardiac computed tomography (CT) scans.
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Methods
Study population and design
Data from the Korea Initiatives on Coronary Artery 
Calcification (KOICA) multicenter registry were ana-
lyzed. This is a retrospective, single ethnicity, multicenter 
observational registry in a self-referral setting for sub-
jects who underwent health checkups at six health care 
centers in South Korea. A total of 93,707 subjects were 
enrolled in the KOICA registry from December 2012 
to August 2016. Self-reported medical questionnaires 
were used to obtain information about medical history. 
All data were obtained during visits to each healthcare 
center. Among the 93,707 subjects from this registry, 
12,441, who underwent at least two CAC scan examina-
tions with available glycemic status data, were included 
in this study. All participants were categorized into three 
groups based on their glycemic status: normal, pre-dia-
betes, and diabetes. Pre-diabetes was defined as a fasting 
plasma glucose (FPG) level of 100–125 mg/dL or hemo-
globin A1c (HbA1c) levels of 5.7–6.4% [12]. Diabetes was 
defined as either an FPG level of ≥  126  mg/dL, HbA1c 
level of ≥  6.5%, a referral diagnosis of diabetes, or cur-
rently receiving anti-diabetic treatment [12, 13].
Coronary artery calcification score was determined 
based on the scoring system previously described by 
Agatston et  al. [14]. CAC progression was defined as 
a difference  ≥  2.5 between the square roots (√) of the 
baseline and follow-up CAC scores (Δ √transformed 
CAC) [15]. The appropriate institutional review board 
committees of each healthcare center approved the study 
protocol. Information on the medical history of hyper-
tension, diabetes, and smoking status for each subject 
was systematically collected. Height, weight, and blood 
pressure were measured during the healthcare center 
visits. All blood samples were obtained after a minimum 
of an 8 h fast and analyzed for triglyceride, high-density 
lipoprotein (HDL) cholesterol, low-density lipoprotein 
(LDL) cholesterol, and glucose levels. In all centers, a 
CT scan to assess CAC was performed using a > 16 slice 
multi-detector CT scanner (Siemens 16-slice Sensation, 
Philips Brilliance 256 iCT, Philips Brilliance 40 channel 
MDCT, and GE 64-slice Lightspeed). All centers per-
formed standard prospective or retrospective methods.
Statistical analysis
Continuous variables are expressed as mean ± standard 
deviation. Categorical variables are presented as absolute 
values and proportions. To compare the characteristics 
of participants among the three glycemic groups, the 
one-way analysis of variance with Bonferroni’s post hoc 
test or the Kruskal–Wallis test was used for continuous 
variables, as appropriate, and the Chi square test for cat-
egorical variables. Univariate logistic regression analysis 
was performed to identify the clinical factors significant 
for CAC progression. Subsequently, multivariate logistic 
regression analysis was used to identify the independ-
ent impact of the glycemic status on CAC progression 
after adjusting the variables with p < 0.05 in the univari-
ate analysis. All statistical analyses were performed using 
the Statistical Package for the Social Sciences version 19 
(SPSS, Chicago, Illinois), and a p value of < 0.05 was con-
sidered significant for all analyses.
Results
Baseline characteristics
The mean age of participants was 52  ±  9  years, and a 
total of 10,472 (84%) participants were males. Among 
them, 6578 (52.9%), 4146 (33.3%), and 1717 (13.8%) were 
categorized in normal, pre-diabetes, and diabetes groups, 
respectively. Table 1 describes the baseline characteristics 
of participants based on their glycemic status. The clini-
cal characteristics such as age, anthropometric indices, 
including body mass index and waist circumference, and 
the incidence of hypertension, dyslipidemia, and smoking 
were significantly different among all groups.
CAC changes based on the glycemic status
Table 2 presents the baseline and follow-up CAC scores 
based on the glycemic status. The average inter-scan 
period was 3.3 ±  1.8  years. The baseline and follow-up 
CAC scores based on glycemic status were significantly 
different (p  <  0.001 for all). The incidence of CAC pro-
gression was significantly different among the three 
groups (normal, 26.3%; pre-diabetes, 30.9%; diabetes, 
46.9%; p < 0.001). Both the Δ √transformed CAC (nor-
mal, 2.1 ± 4.4; pre-diabetes, 2.3 ± 4.3; diabetes, 4.0 ± 6.5; 
p < 0.001) and the annualized Δ √transformed CAC (nor-
mal, 0.5 ± 1.6; pre-diabetes, 0.7 ± 1.6; diabetes, 1.2 ± 2.4; 
p < 0.001) scores were different among the three groups. 
The diabetes group had higher Δ √transformed CAC and 
annualized Δ √transformed CAC scores than the pre-
diabetes and normal groups (p < 0.05, respectively). The 
Δ √transformed CAC between normal and pre-diabetes 
groups were not significantly different. However, the pre-
diabetes group had higher annualized Δ √transformed 
CAC values than the normal group (Fig. 1).
Association between clinical factors and CAC progression
Univariate logistic regression analysis showed that 
age (odds ratio [OR] 1.070; 95% confidential inter-
val [CI] 1.065–1.076), male gender (OR 2.650; 95% 
CI 2.334–3.010), body mass index (OR 1.093; 95% CI 
1.078–1.108), hypertension (OR 2.091; 95% CI 1.930–
2.266), dyslipidemia (OR 1.738; 95% CI 1.600–1.887), 
smoking (OR 1.718; 95% CI 1.571–1.879), and baseline 
CAC score  >  100 (OR 2.818;  95% CI  2.510–3.164) were 
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Table 1 Baseline characteristics
Values are given as mean ± standard deviation or number (%)
HDL high-density lipoprotein, hs-CRP high-sensitivity C-reactive protein, LDL low-density lipoprotein
* p < 0.05 vs. normal, † p < 0.05 vs. pre-diabetes
Normal (n = 6578) Pre-diabetes (n = 4146) Diabetes (n = 1717) p
Age, years 50 ± 8 53 ± 8* 55 ± 9*† < 0.001
Male, n (%) 5423 (82.4) 3523 (85.0) 1526 (88.9) < 0.001
Body mass index, kg/m2 24.1 ± 2.6 25.0 ± 2.8* 25.2 ± 2.9*† < 0.001
Waist circumference, cm 85 ± 8 88 ± 8* 89 ± 8*† < 0.001
Systolic blood pressure, mmHg 118 ± 15 122 ± 15* 122 ± 16* < 0.001
Diastolic blood pressure, mmHg 74 ± 11 77 ± 10* 76 ± 10* < 0.001
Hypertension, n (%) 1568 (24.4) 1544 (39.1) 924 (55.1) < 0.001
Antihypertensive drugs, n (%) 984 (17.0) 1077 (30.2) 675 (43.2) < 0.001
Dyslipidemia, n (%) 1481 (22.6) 1286 (31.0) 701 (40.8) < 0.001
Lipid lowering drugs, n (%) 89 (4.2) 143 (10.8) 76 (18.8) < 0.001
Smoking, n (%) 3919 (64.4) 2552 (68.8) 1166 (74.0) < 0.001
Total cholesterol, mg/dL 196 ± 33 203 ± 34* 190 ± 36*† < 0.001
Triglyceride, mg/dL 130 ± 79 153 ± 96* 156 ± 102* < 0.001
HDL cholesterol, mg/dL 54 ± 16 53 ± 16* 51 ± 16*† < 0.001
LDL cholesterol, mg/dL 122 ± 31 125 ± 33* 115 ± 33*† < 0.001
Creatinine, mg/dL 0.9 ± 0.2 1.0 ± 0.2 1.0 ± 0.2 0.096
hs‑CRP, mg/dL 0.3 ± 1.5 0.4 ± 2.1 0.3 ± 1.7 0.086
Fasting glucose, mg/dL 88 ± 7 100 ± 10* 129 ± 35*† < 0.001
HbA1C, % 5.3 ± 0.3 5.7 ± 0.3* 6.8 ± 1.1*† < 0.001
Table 2 Progression of CAC based on the glycemic status
CAC coronary artery calcium
* p < 0.05 vs. normal, † p < 0.05 vs. pre-diabetes
Normal (n = 6578) Pre-diabetes (n = 4146) Diabetes (n = 1717) p
Baseline
 CAC score 28 ± 110 49 ± 158* 110 ± 319*† < 0.001
 Categorical CAC score < 0.001
  0 4308 (65.5) 2109 (50.9) 554 (32.3)
  1–10 840 (12.8) 608 (14.7) 286 (16.7)
  11–100 1002 (15.2) 924 (22.3) 490 (28.5)
  101–400 324 (4.9) 407 (9.8) 266 (15.5)
  > 400 104 (1.6) 98 (2.4) 121 (7.0)
Follow‑up
 CAC score 71 ± 209 97 ± 235* 220 ± 422*† < 0.001
 Categorical CAC score < 0.001
  0 3657 (55.6) 1732 (41.8) 411 (23.9)
  1–10 550 (8.4) 390 (9.4) 122 (7.1)
  11–100 1321 (20.1) 1048 (25.3) 491 (28.6)
  101–400 751 (11.4) 712 (17.2) 410 (23.9)
  > 400 299 (4.5) 264 (6.4) 283 (16.5)
Inter‑scan period (years) 3.1 (2.0–5.0) 3.0 (1.9–4.5) 3.0 (2.0–4.3) < 0.001
CAC progression, n (%) 1731 (26.3) 1282 (30.9) 805 (46.9) < 0.001
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significantly associated with CAC progression (p < 0.001, 
respectively). Compared with the normal group, the sub-
jects in the pre-diabetes (OR 1.253; 95% CI 1.150–1.366) 
and diabetes (OR 2.471; 95% CI 2.215–2.758) groups had 
an increased risk of CAC progression (p < 0.001, respec-
tively). Multivariate logistic regression analysis showed 
that age (OR 1.069; 95% CI 1.063–1.075), male gender 
(OR 2.422; 95% CI 2.056–2.853), body mass index (OR 
1.061; 95% CI 1.043–1.079), hypertension (OR 1.364; 
95% CI 1.243–1.498), dyslipidemia (OR 1.464; 95% CI 
1.335–1.606), smoking (OR 1.386; 95% CI 1.247–1.540), 
and baseline CAC score > 100 (OR 1.321; 95% CI 1.153–
1.513) were significantly associated with CAC progres-
sion (p < 0.001, respectively). Compared with the normal 
group, the risk of CAC progression was not significantly 
different in pre-diabetes group (OR 0.943; 95% CI 0.856–
1.040), but was significantly higher in the diabetes group 
(OR 1.368; 95% CI 1.206–1.553) (Table 3).
Independent predictors for CAC progression according 
to glycemic status
The results of multivariate logistic regression analysis to 
identify the independent predictors for CAC progression 
according to glycemic status are presented in Table 4. In 
Fig. 1 Change of CAC according to glycemic control status
Table 3 Logistic regression models to identify independ-
ent predictors of CAC progression
CAC coronary artery calcium, CI confidence interval, OR odds ratio
Variables Univariate Multivariate
OR (95% CI) p OR (95% CI) p
Age, years 1.070 (1.065–
1.076)
< 0.001 1.069 (1.063–
1.075)
< 0.001
Male gender 2.650 (2.334–
3.010)
< 0.001 2.422 (2.056–
2.853)
< 0.001
Body mass 
index, kg/m2
1.093 (1.078–
1.108)
< 0.001 1.061 (1.043–
1.079)
< 0.001
Hypertension 2.091 (1.930–
2.266)
< 0.001 1.364 (1.243–
1.498)
< 0.001
Dyslipidemia 1.738 (1.600–
1.887)
< 0.001 1.464 (1.335–
1.606)
< 0.001
Smoking 1.718 (1.571–
1.879)
< 0.001 1.386 (1.247–
1.540)
< 0.001
Baseline CAC 
score > 100
2.818 (2.510–
3.164)
< 0.001 1.321 (1.153–
1.513)
< 0.001
Glycemic status
 Normal 1 – 1 –
 Pre‑diabetes 1.253 (1.150–
1.366)
< 0.001 0.943 (0.856–
1.040)
0.241
 Diabetes 2.471 (2.215–
2.758)
< 0.001 1.368 (1.206–
1.553)
< 0.001
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the normal group, age, male gender, body mass index, 
hypertension, dyslipidemia, smoking, and baseline CAC 
score > 100 were significantly associated with CAC pro-
gression. All factors, except baseline CAC score  >  100, 
were also associated with CAC progression in the pre-
diabetes group. However, only age and male gender were 
independent predictors of CAC progression in the diabe-
tes group.
Discussion
The main finding of this longitudinal study is that dia-
betes has an independent impact on CAC progression; 
however, pre-diabetes is not associated with CAC pro-
gression after adjusting for confounding clinical factors 
in asymptomatic subjects.
Coronary artery calcification is an important marker 
to identify the presence of CAD in asymptomatic sub-
jects. It is a well-known and useful tool to predict adverse 
clinical events [7–10]. Previous cross-sectional studies 
reported the significant risk factors for CAC [16–18].
Recently, the emphasis has been on identifying CAC 
progression in clinical practice because of its increasing 
value in predicting adverse outcomes over the baseline 
CAC score, time between scans, demographics, and CV 
risk factors [11]. Several previous studies have inves-
tigated the predictive value of clinical factors for CAC 
progression. In the Heinz Nixdorf Recall study, CAC 
inevitably progressed with limited influence of CV risk 
factors [19]. Diederichsen et  al. [20] recently evaluated 
the predictive value of 15 biomarkers for CAC incidence 
and progression in asymptomatic middle-aged subjects 
at 5 years follow-up. This prospective study identified the 
association between total and LDL cholesterol and CAC 
incidence, and between phosphate and CAC progression; 
however, 12 other biomarkers did not significantly cor-
relate with CAC. Nevertheless, the impact of glycemic 
status, especially in a pre-diabetic condition, on CAC 
progression in asymptomatic individuals has remained 
uncertain.
In the Multi-Ethnic Study of Atherosclerosis (MESA) 
study, diabetes had the strongest impact on CAC pro-
gression in Black, and the weakest in Hispanic people, 
with intermediate associations in White and Chinese 
people [21]. Furthermore, Wong et al. [22] reported that 
subjects with metabolic syndrome (MetS) and diabetes 
had a greater CAC incidence and absolute progression 
compared with those without these conditions. However, 
the proportion of Asian participants in the study was 
small, and the association between pre-diabetes and CAC 
progression was not evaluated in the MESA study. Other 
studies have evaluated the relationship between pre-
diabetes and the risk of CAD; however, the results were 
inconsistent [5, 23].
Recently, a large observational study reported that 
pre-diabetes was not associated with an increased risk 
of subclinical coronary atherosclerosis in an asympto-
matic Korean population [24]. However, this study did 
not evaluate the atherosclerotic progression because of 
its cross-sectional design. The result of the present study 
is consistent in that pre-diabetes did not have an inde-
pendent impact on CAC progression. Contrary to these 
results, Lee et al. [25] reported that MetS influenced the 
progression of CAD as assessed by CAC scores and coro-
nary CT angiography in a relatively healthy Korean popu-
lation. However, this study included established diabetes 
in the definition of MetS. Considering that the World 
Health Organization recommends that the concept of 
MetS should not be applied in subjects with established 
diabetes [26], pre-diabetes is different from MetS in sub-
jects without established diabetes. Thus, the emphasis 
should not only be on controlling concomitant metabolic 
risk factors but also on preventing the development of 
diabetes to inhibit CAC progression in asymptomatic 
pre-diabetics in clinical practice.
Table 4 Independent predictors for CAC progression according to glycemic status
CAC coronary artery calcium, CI confidence interval, OR odds ratio
Variables Normal Pre-diabetes Diabetes
OR (95% CI) p OR (95% CI) p OR (95% CI) p
Age, years 1.090 (1.080–1.099) < 0.001 1.057 (1.047–1.068) < 0.001 1.036 (1.022–1.050) < 0.001
Male gender 2.447 (1.921–3.118) < 0.001 2.450 (1.857–3.231) < 0.001 1.895 (1.279–2.810) 0.001
Body mass index, kg/m2 1.073 (1.045–1.102) < 0.001 1.051 (1.022–1.081) < 0.001 1.035 (0.997–1.074) 0.069
Hypertension 1.478 (1.284–1.701) < 0.001 1.552 (1.332–1.808) < 0.001 0.910 (0.732–1.131) 0.395
Dyslipidemia 1.658 (1.443–1.905) < 0.001 1.590 (1.365–1.853) < 0.001 0.980 (0.794–1.209) 0.849
Smoking 1.463 (1.256–1.703) < 0.001 1.385 (1.155–1.660) < 0.001 1.170 (0.900–1.523) 0.241
Baseline CAC score > 100 1.685 (1.333–2.131) < 0.001 1.212 (0.974–1.508) 0.085 1.286 (0.994–1.663) 0.056
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The present study identified that diabetes was associ-
ated with an increased risk of CAC progression after 
adjusting for confounding factors. It is well-known that 
vascular calcification is increased in diabetes, and the 
presence of CAC is a strong risk factor for CV events 
[27]. One of the most important mechanisms in diabe-
tes patients was hyperglycemic damage, mainly driven 
by the accumulation of free radicals, which activates vas-
cular inflammation and endothelial dysfunction. In addi-
tion, hyperglycemia itself also increases oxidative stress 
by increasing glucose oxidation [28]. Previous stud-
ies strongly suggested that hyperglycemia may directly 
influence the atherosclerotic process and prognosis in 
established diabetes patients [29–33]. In contrast, sev-
eral studies reported that MetS does not significantly 
influence subclinical atherosclerosis and mortality in 
relatively healthy diabetes patients [34, 35]. In the pre-
sent study, we observed that traditional CV risk factors, 
such as hypertension, dyslipidemia, and smoking, were 
independent determinants for CAC progression in both 
normal and pre-diabetes, but were not associated with 
CAC progression in diabetes patients. Thus, strict gly-
cemic control may be more important to prevent future 
CV events in asymptomatic subjects with diabetes than 
traditional risk factors. Further investigation to identify 
the impact of strict glycemic control on CAC progression 
and prognosis is necessary in asymptomatic patients with 
established diabetes.
Although multiple imaging techniques are available to 
detect the presence of pre-clinical disease, the efficacy of 
these modalities in the risk stratification of asymptomatic 
diabetes patients remains uncertain. Recently, Rassi et al. 
[36] reported that CAC was the most accurate screen-
ing modality for detection of CAD, but that screening for 
carotid plaque using normal coronary CT angiography 
may better characterize stroke risk in asymptomatic dia-
betics. However, this study was performed in only 98 par-
ticipants. Further prospective studies with larger sample 
sizes are required to address this issue.
The present study has several limitations. First, the 
KOICA registry was based on a healthy population 
who underwent health checkups in healthcare centers, 
which may result in a potential selection bias. Second, 
this was a retrospective study, which may be influenced 
by unidentified confounders. Third, participants did not 
undergo an oral glucose tolerance test; however, FPG 
is proven to be a useful parameter in clinical practice 
[37]. Fourth, data on the physical activity of participants 
were unavailable. However, this study was performed on 
asymptomatic subjects in a self-referral setting. Fifth, 
we could not eliminate the possible effects of medica-
tions for hypertension, dyslipidemia, and diabetes on 
the progression of CAC because of the observational 
design. Further large prospective studies are necessary to 
address these issues. Finally, the present study included 
the Korean population only. However, this longitudinal 
study uniquely identified the CAC progression based on 
the glycemic status in asymptomatic individuals, specifi-
cally in the Asian population.
Conclusion
In conclusion, diabetes had an incremental effect on CAC 
progression; however, pre-diabetes was not associated 
with an increased risk of CAC progression after adjusting 
for confounding factors in asymptomatic subjects.
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